A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC)
Status:
Suspended
Trial end date:
2031-06-30
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well axitinib and nivolumab work in treating patients with
TFE/translocation renal cell carcinoma that cannot be removed by surgery (unresectable) or
has spread to other places in the body (metastatic). Axitinib may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal
antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving axitinib and nivolumab
may work better in treating patients with TFE/translocation renal cell carcinoma compared to
standard treatment, including surgery, chemotherapy, or immunotherapy.